Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors
A robust multiplex mass spectrometric assay for screening small-molecule inhibitors of CD73 with diverse inhibition modalities. Credit: Gejing Deng
A new original research article in SLAS Discovery presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.
The methodology described by authors Gejing Deng (Sanofi) et al., uses multiple stable isotope-labeled substrates for carrying out CD73 reactions followed by sample pooling then simultaneously quantifying multiple reaction products using ultra-fast RapidFire-MS/MS.
In contrast to other optical based methodologies, this methodology allows identifying molecules with diverse inhibition modalities and characterizing inhibitors using both recombinant CD73 and CD73+ cells.
This article has been republished from materials provided by SLAS. Note: material may have been edited for length and content. For further information, please contact the cited source.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE